+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Phototherapy Lamps - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 119 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294579
The phototherapy lamps market size is projected to expand from USD 3.79 billion in 2026 and USD 4.04 billion in 2027 to USD 5.54 billion by 2032, registering a CAGR of 6.51% between 2027 and 2032. This report is Segmented by Product Type (LED, Fluorescent, UV, Halogen, and Other), Application (Neonatal Jaundice, Psoriasis, Vitiligo, and More), End User (Hospitals/NICUs, Dermatology Clinics, Homecare, and Other), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Phototherapy Lamps Market Trends and Insights

Rising Incidence of Neonatal Jaundice, Premature Births, and Care Infrastructure

Neonatal jaundice creates a consistent clinical need for the phototherapy lamps market because light therapy remains a standard treatment option for newborns with elevated bilirubin. A 2025 study reported that neonatal jaundice affects 60% of full-term newborns and up to 80% of preterm newborns in the first week of life. A 2025 analysis of Global Burden of Disease data found that the age-standardized mortality rate for neonatal jaundice fell 56.8% between 1990 and 2021, while prevalence rose 41.5% during the same period. Better neonatal survival therefore increases the group of children who need monitoring and treatment, even when mortality declines. A 2026 Pediatric Research analysis reported that Sub-Saharan Africa and South Asia accounted for 68% of incident extreme hyperbilirubinemia cases and 90% of deaths in 2023. Demand in these regions depends on neonatal intensive care capacity, donor-supported procurement, and public investment in newborn care, which links equipment demand to wider health-system development.

Rising Burden of Psoriasis, Vitiligo, Eczema, and Other Photosensitive Disorders

The phototherapy lamps market is also supported by demand from dermatology settings, where narrowband UVB and excimer treatment are used for psoriasis, vitiligo, eczema, and related conditions. The American Medical Association CPT Editorial Panel approved updates to codes 96920-96922 that extend reimbursable targeted phototherapy indications to vitiligo, atopic dermatitis, and alopecia areata from January 1, 2027. STRATA Skin Sciences stated that the coverage change could expand the addressable patient group to more than 30 million people in the United States. Aetna’s clinical policy bulletin classified excimer laser, PUVA, and narrowband UVB as medically necessary for vitiligo after inadequate response to topical agents. A 2026 multicenter study reported an 85.5% response rate for XTRAC 308-nm excimer treatment combined with oral JAK inhibitors in pediatric progressive vitiligo, compared with 53.8% in a tacrolimus control group. These coverage and clinical developments support a broader role for supervised light treatment in specialty dermatology.

High Acquisition, Lifecycle, Safety, and Refurbished-Equipment Constraints

Advanced LED systems can require capital spending that public hospitals in lower-income settings find difficult to fund. The burden continues after purchase because calibration, recertification, replacement parts, and maintenance add to lifecycle costs. These constraints slow purchasing within the phototherapy lamps market where procurement decisions are tied to annual public budgets. A 2025 open-source device study found that a neonatal phototherapy unit meeting American Academy of Pediatrics and UNICEF irradiance specifications could be fabricated with USD 93.00 in material costs. The large cost difference between low-cost designs and commercial systems helps explain the continued use of refurbished equipment in South Asia, Sub-Saharan Africa, and parts of Latin America. Used equipment can defer new-device purchases and reduce replacement-cycle revenues. Safety considerations also remain material, particularly for homecare products, because dose accuracy, thermal exposure, and appropriate clinical supervision affect acceptance.

Other drivers and restraints analyzed in the detailed report include:

  1. Migration From Fluorescent and Halogen Lamps to LED Phototherapy Lamps
  2. Growth of Home-Based, Portable, and Family-Centered Phototherapy
  3. Stringent Device Approval and Clinical Compliance Requirements

Segment Analysis

LED lamps held 68.3% of revenue in 2026. Their position reflects targeted output at bilirubin-relevant wavelengths, longer operating life, lower heat exposure, and improved consistency compared with fluorescent alternatives. Hospitals are also giving more weight to irradiance precision because infant phototherapy safety requirements have strengthened. Fluorescent lamps remain in use in resource-constrained hospitals where installed systems can remain in service for long periods. UV lamps retain a specialist role in psoriasis, vitiligo, eczema, and atopic dermatitis care. Halogen lamps continue to lose relevance as hospitals replace older equipment during upgrade cycles.

LED lamps are forecast to grow at an 8.5% CAGR from 2027 to 2032, exceeding the total phototherapy lamps market growth rate. A 2025 European Journal of Pediatrics pilot study found that the Jauni wearable LED device enabled 83% of treated newborns to complete phototherapy within 48 hours. The device delivered irradiance of 25-30 µW/cm²/nm at 470 nm, and the study reported no serious adverse events. Wearable LED formats therefore widen the range of potential care settings without changing the clinical purpose of phototherapy. Suppliers can also use product tiers, from standard overhead lamps to connected premium systems, to address differing hospital, clinic, and homecare budgets.

Complete Report Scope:

  • By Product Type
    • LED Phototherapy Lamps
    • Fluorescent Phototherapy Lamps
    • UV Phototherapy Lamps
    • Halogen Phototherapy Lamps
    • Other Product Types
  • By Application
    • Neonatal Jaundice Treatment
    • Psoriasis Treatment
    • Vitiligo Treatment
    • Eczema and Atopic Dermatitis Treatment
    • Acne and Cosmetic Dermatology Treatment
    • Other Applications
  • By End User
    • Hospitals and Neonatal Intensive Care Units
    • Dermatology Clinics and Specialty Clinics
    • Homecare Settings
    • Other End Users
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 41.3% of the phototherapy lamps market in 2026. The region benefits from dense NICU capacity, established specialist dermatology networks, and insurance structures that support replacement demand. Cigna’s July 2025 policy update and Elevance Health’s related coverage revision expanded access to home phototherapy for psoriasis, eczema, and vitiligo. The changes increased the practical importance of residential procurement in a region previously led by institutional purchases. Natus Sensory and Canadian Hospital Specialties entered a multi-year agreement in February 2026 to expand access to newborn-care products across Canadian health systems. The agreement covers phototherapy, hearing screening, and NICU connectivity, showing how suppliers are combining product access with education and distribution. Food and Drug Administration clearance remains a central compliance factor for new products in the United States. The phototherapy lamps market has higher per-capita use in North America because of long-standing investment in neonatal and specialist care. Connected home devices are likely to be most relevant where payer coverage and remote clinical oversight are both available.

Asia-Pacific is forecast to grow at a 7.5% CAGR from 2027 to 2032. High birth volumes, expanding NICU capacity, and greater access to specialist dermatology support the region’s demand profile. The region combines large public hospital systems with growing private care networks, creating demand across a broad range of price points. India’s device-production incentive framework and unmet neonatal-care needs support interest in lower-cost LED platforms for hospitals and community settings. Phoenix Medical Systems and Nice Neotech were identified in the supplied draft as domestic suppliers scaling affordable LED equipment. Japan and South Korea are more mature settings where interest is moving toward workflows that combine bilirubin measurement with phototherapy delivery. Regulatory requirements vary across the region and add complexity for international suppliers. The phototherapy lamps market size in Asia-Pacific is also shaped by the ability of providers to add capacity beyond major urban hospitals. Affordable LED equipment and portable formats are important where health systems are extending care to smaller facilities.

Europe, the Middle East and Africa, and South America show different demand conditions within the wider phototherapy lamps market. Germany and France have supported wearable-phototherapy clinical trials, while European Union Medical Device Regulation compliance can lengthen registration processes and favor suppliers with established regulatory teams. The United Kingdom’s Photonet audit program tracks UVB treatment outcomes across Scottish dermatology centers, supporting procurement that emphasizes documented performance. Gulf Cooperation Council countries are investing in premium NICU infrastructure through hospital expansion and medical tourism. Sub-Saharan Africa has substantial unmet neonatal need, which supports the relevance of solar-powered and battery-operated LED solutions where electrification is limited. In South America, Brazil’s unified public health procurement system favors cost-competitive suppliers, including Fanem Ltda. Argentina’s macroeconomic volatility can interrupt capital-equipment purchasing across the region. These mixed geographies require suppliers to align product design, price, power requirements, and distribution support with local care capacity. European compliance factors, public purchasing rules, and infrastructure limits elsewhere can all affect the speed of adoption. The phototherapy lamps market share across these regions is therefore shaped less by a single purchasing model and more by local clinical capacity and procurement conditions.



List of Companies Covered in this Report:

  1. ATOM MEDICAL Corp.
  2. Beurer
  3. Bistos Co., Ltd.
  4. Daavlin Company, The
  5. Dragerwerk
  6. Fanem Ltda.
  7. Fanem Ltda.
  8. GE HealthCare Technologies Inc.
  9. Herbert Waldmann GmbH & Co. KG
  10. Ibis Medical Equipment and Systems Pvt. Ltd.
  11. National Biological Corporation
  12. Natus Medical
  13. Nice Neotech Medical Systems Pvt. Ltd.
  14. Ningbo David Medical Device
  15. PhotoMedex
  16. Phothera Phototherapy
  17. Phoenix Medical Systems
  18. Shanghai SIGMA High-tech Co., Ltd.
  19. Shenzhen Kaiyan Medical Equipment Co., Ltd.
  20. STRATA Skin Sciences, Inc.
  21. Thera B Medical Products
  22. UVBioTek
  23. Xuzhou Kaixin Electronic Equipment Co., Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Neonatal Jaundice and Premature Births
4.2.2 Rising Burden of Psoriasis, Vitiligo, Eczema, and Other Photosensitive Disorders
4.2.3 Migration From Fluorescent and Halogen Lamps to LED Phototherapy Lamps
4.2.4 Expansion of Neonatal Intensive Care and Dermatology Infrastructure
4.2.5 Growth of Home-Based and Portable Phototherapy
4.2.6 Wearable and Family-Centered Neonatal Phototherapy Designs
4.3 Market Restraints
4.3.1 High Acquisition and Lifecycle Costs of Advanced Systems
4.3.2 Treatment-Related Safety and Exposure Risks
4.3.3 Stringent Device Approval and Clinical Compliance Requirements
4.3.4 Replacement Demand Displaced by Refurbished and Used Equipment
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat Of New Entrants
4.7.2 Bargaining Power Of Buyers
4.7.3 Bargaining Power Of Suppliers
4.7.4 Threat Of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product Type
5.1.1 LED Phototherapy Lamps
5.1.2 Fluorescent Phototherapy Lamps
5.1.3 UV Phototherapy Lamps
5.1.4 Halogen Phototherapy Lamps
5.1.5 Other Product Types
5.2 By Application
5.2.1 Neonatal Jaundice Treatment
5.2.2 Psoriasis Treatment
5.2.3 Vitiligo Treatment
5.2.4 Eczema and Atopic Dermatitis Treatment
5.2.5 Acne and Cosmetic Dermatology Treatment
5.2.6 Other Applications
5.3 By End User
5.3.1 Hospitals and Neonatal Intensive Care Units
5.3.2 Dermatology Clinics and Specialty Clinics
5.3.3 Homecare Settings
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
6.3.1 ATOM MEDICAL Corp.
6.3.2 Beurer GmbH
6.3.3 Bistos Co., Ltd.
6.3.4 Daavlin Company, The
6.3.5 Drägerwerk AG & Co. KGaA
6.3.6 Fanem Ltda.
6.3.7 Fanem Ltda.
6.3.8 GE HealthCare Technologies Inc.
6.3.9 Herbert Waldmann GmbH & Co. KG
6.3.10 Ibis Medical Equipment and Systems Pvt. Ltd.
6.3.11 National Biological Corporation
6.3.12 Natus Medical Incorporated
6.3.13 Nice Neotech Medical Systems Pvt. Ltd.
6.3.14 Ningbo David Medical Device Co., Ltd.
6.3.15 PhotoMedex, Inc.
6.3.16 Phothera Phototherapy
6.3.17 Phoenix Medical Systems Pvt. Ltd.
6.3.18 Shanghai SIGMA High-tech Co., Ltd.
6.3.19 Shenzhen Kaiyan Medical Equipment Co., Ltd.
6.3.20 STRATA Skin Sciences, Inc.
6.3.21 Thera B Medical Products
6.3.22 UVBioTek
6.3.23 Xuzhou Kaixin Electronic Equipment Co., Ltd.
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ATOM MEDICAL Corp.
  • Beurer GmbH
  • Bistos Co., Ltd.
  • Daavlin Company, The
  • Drägerwerk AG & Co. KGaA
  • Fanem Ltda.
  • GE HealthCare Technologies Inc.
  • Herbert Waldmann GmbH & Co. KG
  • Ibis Medical Equipment and Systems Pvt. Ltd.
  • National Biological Corporation
  • Natus Medical Incorporated
  • Nice Neotech Medical Systems Pvt. Ltd.
  • Ningbo David Medical Device Co., Ltd.
  • PhotoMedex, Inc.
  • Phothera Phototherapy
  • Phoenix Medical Systems Pvt. Ltd.
  • Shanghai SIGMA High-tech Co., Ltd.
  • Shenzhen Kaiyan Medical Equipment Co., Ltd.
  • STRATA Skin Sciences, Inc.
  • Thera B Medical Products
  • UVBioTek
  • Xuzhou Kaixin Electronic Equipment Co., Ltd.